Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459455 | 1.00 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL1847774 | 1.00 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL1847773 | 1.00 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL12578272 | 1.00 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL1847869 | 0.82 | EPHX2 (0.57) | EPHX2P2RX7LMNASMN1; SMN2MEN1 | |
| SCHEMBL1847868 | 0.82 | EPHX2 (0.57) | EPHX2P2RX7LMNASMN1; SMN2MEN1 | |
| SCHEMBL1846688 | 0.78 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL1846690 | 0.78 | EPHX2 (0.49) | EPHX2P2RX7CTSLLMNASMN1; SMN2 | |
| SCHEMBL1845008 | 0.75 | EPHX2 (0.59) | EPHX2P2RX7LMNASMN1; SMN2MEN1 | |
| SCHEMBL12578532 | 0.75 | EPHX2 (0.59) | EPHX2P2RX7LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | EPHX2 2166/4885P2RX7 952/4885CTSL 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.